The Spark – Der Technologiepreis: Dieses Start-up bringt Pharma-Rivalen dazu, Daten zu teilen
KI könnte die Pharmaforschung beschleunigen – doch die entscheidenden Daten bleiben unter Verschluss. Das Start-up Apheris bietet einen Ausweg. Und wird bei „The Spark“ prämiert.
Munich: In the realm of medical progress, artificial intelligence (AI) promises immense value. However, pharma companies and research institutions are reluctant to share the necessary data, complicating the development of algorithms and models. A Berlin-based startup, Apheris, aims to provide a solution to this dilemma. By utilizing decentralized networks, Apheris enables pharmaceutical firms to conduct drug research without exposing sensitive data.
The company's innovative approach allows models to be trained directly at the source, with results—specifically, the model parameters—later combined. Apheris secured the third place at the "The Spark" technology award, presented by Handelsblatt and McKinsey. The jury commended the "fundamentally new approach" in drug development, emphasizing not a new AI model but the access to data.
The founder, Robin Röhm, identified this problem in his first startup, Janus Genomics, where he observed the difficulty in exchanging confidential patient data for research. This led him to develop an idea, ultimately founding Apheris with Michael Höh in 2019.
Written by urgent.news from Handelsblatt's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
